Published in J Virol on November 21, 2007
Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog (2009) 2.29
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol (2009) 1.73
Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol (2008) 1.64
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
Prior infection with classical swine H1N1 influenza viruses is associated with protective immunity to the 2009 pandemic H1N1 virus. Influenza Other Respir Viruses (2010) 1.25
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. Clin Infect Dis (2011) 1.18
Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine (2009) 1.16
Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses. J Virol (2010) 1.12
Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One (2010) 1.06
Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr (2010) 1.05
Stability of influenza vaccine coated onto microneedles. Biomaterials (2012) 1.04
Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm Res (2010) 1.03
Protective effect of ginseng polysaccharides on influenza viral infection. PLoS One (2012) 1.03
Immunization with 1976 swine H1N1- or 2009 pandemic H1N1-inactivated vaccines protects mice from a lethal 1918 influenza infection. Influenza Other Respir Viruses (2011) 1.02
Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol (2010) 1.01
Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets. J Infect Dis (2011) 0.98
Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech (2010) 0.98
Case-based surveillance of influenza hospitalizations during 2004-2008, Colorado, USA. Emerg Infect Dis (2009) 0.98
Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res (2013) 0.97
Protective effect of Korean red ginseng extract on the infections by H1N1 and H3N2 influenza viruses in mice. J Med Food (2012) 0.97
Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Mol Ther (2014) 0.95
Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol (2010) 0.95
Immunosignatures can predict vaccine efficacy. Proc Natl Acad Sci U S A (2013) 0.93
Virus-like particles as universal influenza vaccines. Expert Rev Vaccines (2012) 0.93
Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol (2011) 0.90
Antibody responses and cross protection against lethal influenza A viruses differ between the sexes in C57BL/6 mice. Vaccine (2011) 0.90
Why do adaptive immune responses cross-react? Evol Appl (2008) 0.89
Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination. Immunology (2014) 0.88
Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol (2012) 0.86
Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration. Influenza Other Respir Viruses (2013) 0.82
A mechanistic study on the destabilization of whole inactivated influenza virus vaccine in gastric environment. PLoS One (2013) 0.82
Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clin Vaccine Immunol (2013) 0.81
Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination. PLoS One (2013) 0.81
Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity. Vaccine (2014) 0.81
Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunol (2013) 0.81
Immunogenicity of low-pH treated whole viral influenza vaccine. Virology (2011) 0.81
Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model. Clin Vaccine Immunol (2014) 0.80
Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. J Control Release (2015) 0.80
Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus. Vaccine (2010) 0.79
Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung. Nanomedicine (Lond) (2014) 0.78
Induction of humoral and cell-mediated immune responses by hepatitis B virus epitope displayed on the virus-like particles of prawn nodavirus. Appl Environ Microbiol (2014) 0.78
A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus. J Immunol (2016) 0.77
Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease. Virology (2014) 0.77
Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses. J Control Release (2016) 0.77
Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles. PLoS One (2015) 0.77
Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins. PLoS One (2015) 0.77
Repeated Low-Dose Influenza Virus Infection Causes Severe Disease in Mice: a Model for Vaccine Evaluation. J Virol (2015) 0.75
Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines. PLoS Comput Biol (2016) 0.75
Distinct B-cell populations contribute to vaccine antigen-specific antibody production in a transgenic mouse model. Immunology (2014) 0.75
The osmotic stress response of split influenza vaccine particles in an acidic environment. Arch Pharm Res (2013) 0.75
Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate. Antiviral Res (2017) 0.75
Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection. Biochem Biophys Res Commun (2017) 0.75
Advances in the study of nodavirus. PeerJ (2017) 0.75
Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol (2005) 10.77
Humoral immunity due to long-lived plasma cells. Immunity (1998) 6.35
Gangliosides and membrane receptors for cholera toxin. Biochemistry (1973) 4.81
Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol (1994) 3.86
Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol (1995) 3.32
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J Immunol (1997) 1.95
Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol (1995) 1.88
Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J Immunol (2001) 1.86
Mucosal adjuvants. Vaccine (2005) 1.86
Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol (2000) 1.85
Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine (2003) 1.78
Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol (2007) 1.78
Murine model for evaluation of protective immunity to influenza virus. Vaccine (1993) 1.73
Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology (1992) 1.68
Production of interferon-gamma by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am J Pathol (2001) 1.63
Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology (1999) 1.63
Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis (2000) 1.61
Protection against a lethal avian influenza A virus in a mammalian system. J Virol (1999) 1.60
The mechanism of cholera toxin adjuvanticity. Res Immunol (1998) 1.51
Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol (2000) 1.44
Long-term maintenance of virus-specific effector memory CD8+ T cells in the lung airways depends on proliferation. J Immunol (2002) 1.42
Current status of live attenuated influenza virus vaccine in the US. Virus Res (2004) 1.40
Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol (1992) 1.38
Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine (2006) 1.32
Respiratory and systemic humoral and cellular immune responses of pigs to a heterosubtypic influenza A virus infection. J Gen Virol (2001) 1.30
Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. J Immunol (1989) 1.18
Evaluation of live and inactivated influenza A virus vaccines in a mouse model. J Infect Dis (1982) 1.10
Gamma interferon is not required for mucosal cytotoxic T-lymphocyte responses or heterosubtypic immunity to influenza A virus infection in mice. J Virol (2000) 1.03
Calcium signaling through phospholipase C activates dendritic cells to mature and is necessary for the activation and maturation of dendritic cells induced by diverse agonists. Clin Diagn Lab Immunol (2004) 0.95
Variation in frequency of natural reinfection with influenza A viruses. J Med Virol (1983) 0.94
Cellular immune responses to influenza. Dev Biol (Basel) (2003) 0.92
Intranasal immunization with influenza virus and Korean mistletoe lectin C (KML-C) induces heterosubtypic immunity in mice. Vaccine (2007) 0.86
Influenza H5 virus escape mutants: immune protection and antibody production in mice. Virus Res (2004) 0.81
Presence of antigen-specific long-term memory cells in systemic lymphoid tissues as well as locally in the gut lamina propria following oral immunization with cholera toxin adjuvant. Adv Exp Med Biol (1995) 0.81
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Gain-of-function experiments on H7N9. Science (2013) 3.67
Dissolving polymer microneedle patches for influenza vaccination. Nat Med (2010) 3.24
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One (2009) 1.95
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A (2009) 1.82
Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One (2009) 1.78
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A (2008) 1.61
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One (2011) 1.44
Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One (2010) 1.44
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
Influenza virus inhibits ENaC and lung fluid clearance. Am J Physiol Lung Cell Mol Physiol (2004) 1.40
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine (2006) 1.33
Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine (2006) 1.32
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26
Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26
Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol (2007) 1.25
A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine (2008) 1.24
Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis (2011) 1.24
Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology (2006) 1.23
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol (2010) 1.22
Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A (2010) 1.22
Inhibition of influenza infection by glutathione. Free Radic Biol Med (2003) 1.20
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol (2003) 1.20
TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc Natl Acad Sci U S A (2002) 1.19
A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A (2004) 1.18
Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother (2005) 1.17
Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology (2007) 1.16
Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression. J Virol (2002) 1.16
Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology (2005) 1.16
Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine (2009) 1.16
Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine (2009) 1.14
Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep (2012) 1.14
Nonpeptide inhibitors of measles virus entry. J Med Chem (2006) 1.08
Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology (2003) 1.07
Transmission studies resume for avian flu. Science (2013) 1.07
Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One (2010) 1.06
H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine (2011) 1.06
Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS One (2011) 1.06
Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release (2010) 1.05
Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine (2003) 1.05
Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain. J Virol (2004) 1.04
Stability of influenza vaccine coated onto microneedles. Biomaterials (2012) 1.04
Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm Res (2010) 1.03
Protective effect of ginseng polysaccharides on influenza viral infection. PLoS One (2012) 1.03
Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res (2010) 1.03
Local response to microneedle-based influenza immunization in the skin. MBio (2012) 1.03
Genetic control of DH reading frame and its effect on B-cell development and antigen-specifc antibody production. Crit Rev Immunol (2010) 1.02
Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol (2010) 1.01
Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis (2011) 1.01
MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination. J Virol (2011) 1.00
Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand. Clin Vaccine Immunol (2012) 0.99
Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech (2010) 0.98
Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res (2009) 0.98
Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res (2013) 0.97